RPRX — Royalty Pharma Share News
0.000.00%
Last trade - 00:00- $36.72bn
- $47.80bn
- $2.38bn
Brief: Royalty Pharma Announces Dividend Increase
Brief: Royalty Pharma Acquires Remaining Royalty Interest In Roche’S Evrysdi For $240 Million
Brief: Royalty Pharma Acquires Royalty Interest In Nuvalent’S Neladalkib And Zidesamtinib For Up To $315 Million
Brief: Denali Therapeutics And Royalty Pharma Announce $275 Million Royalty Funding Agreement
Royalty Pharma Q3 Portfolio Receipts up 11%, guidance raised
Brief: Royalty Pharma To Announce Third Quarter 2025 Financial Results On November 5, 2025
Brief: Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
Brief: Royalty Pharma Targets Mid-Teens Annual Shareholder Return Over Next 5 Years
Brief: Royalty Pharma Says It Announces Pricing Of $2.0 Billion Of Senior Unsecured Notes
Brief: Zenas Biopharma And Royalty Pharma Enter Into Obexelimab Funding Agreement For Up To $300 Million
Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million (updated)
Brief: Beigene And Unit Sign Royalty Purchase Agreement With Royalty Pharma PLC's Unit
Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million
Royalty Pharma PLC reports results for the quarter ended June 30 - Earnings Summary
Brief: Royalty Pharma Reports Second Quarter 2025 Results
Revolution falls after deal with Royalty Pharma for its cancer drug
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug (updated)
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
Brief: Royalty Pharma Completes The Acquisition Of Its External Manager